Juan Jiao

Dr. Juan Jiao


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2025 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
FZFuyu Zhao
Fuyu Zhao
JZJianan Zhao
Jianan Zhao
YLYang Li
Yang Li
CSChenyang Song
Chenyang Song
YCYaxin Cheng
Yaxin Cheng
CCcen chang
cen chang
Objective: Fibromyalgia (FM) is a complex autoimmune disorder characterized by widespread pain and fatigue, with significant diagnostic challenges due to the absence of specific biomarkers. This study aims to identify and validate potential genetic markers for FM to facilitate earlier diagnosis and intervention.Methods: We analyzed gene expression data from the Gene Expression Omnibus (GEO) to identify differentially expressed genes (DEGs) associated with FM. Comprehensive enrichment analyses, including Gene Ontology (GO), the Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome pathways, were performed to elucidate the biological functions and disease associations of the candidate genes. We used the eXtreme Gradient Boosting (XGBoost) algorithm to develop a diagnostic model, which was validated using independent datasets.Results: Three genes, namely, dual-specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3), regulator of G protein signaling 17 (RGS17), and Rho guanine nucleotide exchange factor 37 (ARHGEF37), were identified as key biomarkers for FM. These genes are implicated in critical processes such as ion homeostasis, cell signaling, and neurobiological functions, which are perturbed in FM. The diagnostic model demonstrated robust performance, with an area under the curve (AUC) of 0.8338 in the training set and 0.8178 in the validation set, indicating its potential utility in clinical settings.Conclusion: The study successfully identifies three diagnostic biomarkers for FM, supported by both bioinformatics analysis and machine learning models. These findings could significantly improve diagnostic accuracy for FM, leading to better patient management and treatment outcomes.

1 November 2019
Verified
Journal Article
Closed access
JJJuan Jiao
Juan Jiao
IRI. J. Russell
I. J. Russell
WWW. Wang
W. Wang
JWJ. Wang
J. Wang
YZY. -Y. Zhao
Y. -Y. Zhao
QJQuan Jiang
Quan Jiang

5 September 2017 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
QJQuan Jiang
Quan Jiang
XTXiaopo Tang
Xiaopo Tang
XCXian-Chun Chen
Xian-Chun Chen
HXHong Xiao
Hong Xiao
PLPing Liu
Ping Liu
JJJuan Jiao
Juan Jiao
Chinese external therapy (CET) is a topical application with mainly Chinese herb medicine therapy with thousands of years of historical implications and is a clinical routine that is commonly used for relieving joint-related symptoms in patients with arthritis in Chinese hospitals. However, there is a paucity of modern medical evidence to support its effectiveness and safety. Thus, we propose to implement a randomized, double-blinded, placebo-controlled clinical trial in patients with rheumatoid arthritis (RA) using, as the experimental intervention, topical application of a hospital-compounded gel preparation of Tripterygium wilfordii Hook F (TwHF). This study will be an 8-week double-blinded, randomized, placebo-controlled clinical trial conducted at Guang’anmen Hospital in Beijing, China, and 168 patients with moderately active RA will be randomly assigned with a 1:1 ratio to apply a topical gel preparation containing TwHF or placebo. The primary outcome variable will be the proportion of subjects, by study group, to achieve a 20% improvement in the American College of Rheumatology criteria (ACR20) by week 8. Secondary outcome measures to be assessed at weeks 4 or 8 will include: measurement of ACR20 response rate at week 4, ACR50 response rate, the changes in DAS28 score, and joint synovitis classification assessment monitored by musculoskeletal ultrasound. Safety evaluations conducted at weeks 4, 8 and 12 will be based on spontaneous complaints by the study subjects, but special emphasis will be focused on cutaneous allergy and alterations of menstruation in premenopausal female participants. Statistical analyses will be performed using the intention to treat analysis data set. This proposed clinical trail is designed to evaluate the efficacy and safety of CET based on a single topically-applied agent in a relatively large patient population with RA. This study protocol gives a detailed description of the usage and dosage of the topical compound TwHF gel and the methodology of this study. In addition, it is hoped that the outcomes of this study will be viewed as supporting the generalizability of CET in the setting of inflammatory rheumatic diseases. The results of this study are expected to have important public health implications for Asian RA patients that currently utilize CET as a complimentary treatment. Clinical trial gov Identifier: NCT02818361 . Registrated on Jun. 15, 2016.

18 January 2025 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
YWYidan Wang
Yidan Wang
PLPengxiao Liu
Pengxiao Liu
ZLZihao Li
Zihao Li
SWShiya Wu
Shiya Wu
MLMeijuan Long
Meijuan Long
ZXZheng Xie
Zheng Xie
Fibromyalgia is a chronic condition marked by widespread pain and various accompanying symptoms. Compared to healthy individuals and other rheumatic disease patients, it leads to more severe symptoms and a lower quality of life. Whether fibromyalgia patients in a mild activity or remission stage still experience core symptoms remains unclear. To compare the severity of clinical symptoms and quality of life (QOL) in patients with remission or mild fibromyalgia (RFM) and remission or low disease activity in rheumatoid arthritis (RRA) patients and healthy controls (HCs) to investigate whether fibromyalgia in a stable stage can be disease-free. This cross-sectional study evaluated a total of 266 RFM and 252 RRA patients and 50 HCs using Revised Fibromyalgia Impact Questionnaire (FIQR), Widespread Pain Index (WPI), Pain Visual Analogue Scale (VAS), Numerical Rating Scale, Multidimensional Fatigue Inventory (MFI-20), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI), and Short Form-36 Health Status Questionnaire (SF-36). The FIQR total score and pain VAS, MFI, and PSQI scores were higher in RFM and RRA patients compared to HCs (P < 0.001). RFM patients had higher BDI and WPI scores than RRA patients (P < 0.001). The majority of RFM patients (97.4%) had more than two pain sites, with moderate-to-severe pain (78.2%), sleep disorders (85.0%), and depression (53.4%), all of which were significantly higher than those in RRA patients (P < 0.001). RFM patients also had lower scores in SF-36 physical and mental component summaries and subscores for role physical, pain index, general health perception, vitality, and mental health index, but a higher social functioning score than RRA patients (P < 0.001). Despite being in a mild activity or remission stage, RFM patients experience more severe symptoms and poorer QOL than RRA patients. Therefore, individualized evaluation and intensive management are required. ClinicalTrials.gov Identifier: NCT02449395, registered on May 20, 2015.

2 February 2023 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
YLYang Li
Yang Li
MLMeijuan Long
Meijuan Long
YWYidan Wang
Yidan Wang
YLYanting Li
Yanting Li
ZLZihao Li
Zihao Li
JJJuan Jiao
Juan Jiao
Full Papers; Authors: Y. Li, M. Long, Y. Wang, Y. Li, Z. Li, J. Jiao

19 October 2022 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
YLYan‐Ting Li
Yan‐Ting Li
QJQuan Jiang
Quan Jiang
YJYuan Jia
Yuan Jia
YZYong‐Feng Zhang
Yong‐Feng Zhang
YXYu‐Ya Xiao
Yu‐Ya Xiao
JJJuan Jiao
Juan Jiao